Selinexor and Backbone Treatments of Multiple Myeloma Patients

Official Title

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma

Summary:

This study will independently assess the efficacy and safety of two combination therapies for the treatment of patients with relapsed/refractory multiple myeloma (RR MM): selinexor + dexamethasone + pomalidomide (SdP), selinexor + dexamethasone + bortezomib (SdB), and selinexor + dexamethasone + lenalidomide (SdL).

Trial Description

Primary Outcome:

  • Maximal Tolerated Dose (MTD) and Recommended Phase 2 dose (RP2D) for Selinexor
Secondary Outcome:
  • Number of patients with Adverse Events as a measure of safety and tolerability
Multi-centre, open-label, randomized (for dose schedule) clinical study with dose escalation (Phase 1) and expansion (Phase 2) stages to independently assess the maximum tolerated dose (MTD,) efficacy, and safety of selinexor + dexamethasone + pomalidomide (SdP), selinexor + dexamethasone + bortezomib (SdB), and selinexor + dexamethasone + lenalidomide (SdL), in patients with relapsed/refractory multiple myeloma (RR MM).

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society